ArticleAntimicrobial agents and chemotherapy2006
Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review.Cancer letters · 2016Pooled it
- Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2009Guideline
- Small Molecule Inhibition of Mononegavirales RNA Polymerases.Journal of medical virology · 2026Review
- Mechanistic insights and emerging applications of human metapneumovirus (HMPV) treatment: From molecular design to translational immunity.Folia microbiologica · 2026Review
- Repurposing antiviral drugs targeting RNA viruses: A focus on the fusion protein of human metapneumovirus.Northern clinics of Istanbul · 2026Article
- Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment.Viruses · 2025Review
- Interplay between endogenous hormones and immune systems in human metapneumovirus pathogenesis and management.Frontiers in pharmacology · 2025Review
- Repurposing Metal-Based Therapeutics for Human Metapneumovirus (HMPV): An Integrative Computational Approach.Bioinorganic chemistry and applications · 2025Article
- Respiratory illness virus infections with special emphasis on COVID-19.European journal of medical research · 2022Review
- Prophylactic and therapeutic approaches for human metapneumovirus.Virusdisease · 2018Review
- Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.Open forum infectious diseases · 2018Article
- Human metapneumovirus - what we know now.F1000Research · 2018Review
- Severe Respiratory Viral Infections: New Evidence and Changing Paradigms.Infectious disease clinics of North America · 2017Review
- Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes.Cancer · 2017Article
- Antiviral therapy for respiratory viral infections in immunocompromised patients.Expert review of anti-infective therapy · 2017Review
- Viral Pneumonia and Acute Respiratory Distress Syndrome.Clinics in chest medicine · 2017Review
- Review
- Human metapneumovirus in the preterm neonate: current perspectives.Research and reports in neonatology · 2016Article
- Immune Response to Human Metapneumovirus Infection: What We Have Learned from the Mouse Model.Pathogens (Basel, Switzerland) · 2015Review
- New Approaches for Immunization and Therapy against Human Metapneumovirus.Clinical and vaccine immunology : CVI · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human metapneumovirus (hMPV)-infected BALB/c mice were treated with ribavirin (40 mg/kg of body weight twice a day intraperitoneally), corticosterone (0.2 mg/ml in water), or both modalities. Ribavirin significantly decreased both hMPV replication in lungs (by 5 log10) and global pulmonary inflammation on day 5 postinfection, whereas glucocorticoids reduced only alveolar and interstitial inflammation, compared to controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.